This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BIO-Europe Spring

€500 savings end in:

  • 00
  • 00
  • 00
  • 00
March 18–20, 2024 | Barcelona, SpainMarch 26–27, 2024 | Digital Partnering

Pharos iBio


Pharos iBio is a clinical stage biotech company that develops novel drug for rare and refractory diseases using AI-based new drug discovery platform, "Chemiverse". The Chemiverse Platform consists of 9 modules including “Deep RECOM” and “ChemGEN” to achieve “Best Target and Best Chemical". It is the company’s proprietary platform using big data for each module and AI (Artificial Intelligence)-based algorithms for entire drug discovery process from Target ID to Drug Candidate. The company also accelerates the drug development through Open Innovation for the optimization of the drugs. PHI-101 was derived from "Chemiverse" making the drug optimization and exploring new indications. The Phase I clinical trials of PHI-101 for Acute Myeloid Leukemia and ovarian cancer are ongoing. The company seeks for partners who is willing together for further developments of the drugs or collaborations for the novel drug discovery and optimization.